---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-24-000038"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:51:40.128163+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mineralys reports Q2 net loss $41M; Advance-HTN trial ~90% enrolled, on track for Q1 2025 data

## Summary
- Net loss of $41.0M for Q2 2024 vs $12.1M in Q2 2023; cash and investments of $311.1M as of June 30, 2024.
- Advance-HTN pivotal trial ~90% enrolled; topline data expected Q1 2025 after FDA alignment on primary endpoint.
- Launch-HTN Phase 3 enrollment ahead of schedule; topline data on track for 2H 2025.
- Explore-CKD Phase 2 trial enrollment ramping; topline data expected 1H 2025.
- Cash runway into 2026 covers planned clinical studies and corporate operations.

## SEC filing metadata
- accession: 0001933414-24-000038
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000038/0001933414-24-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000038/mlys-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-24-000038
- JSON: https://secwatch.observer/filing/0001933414-24-000038.json
- Plain text: https://secwatch.observer/filing/0001933414-24-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.